Biologic Therapy for Psoriasis
The New Therapeutic Frontier
Prashant Singri, MD;
Dennis P. West, PhD;
Kenneth B. Gordon, MD
Arch Dermatol. 2002;138:657-663.
Objectives (1) To develop a clinically useful model with which dermatologists can
understand the potential uses of biologic therapy for psoriasis and understand
the potential differences among these novel drugs, (2) to discuss the process
by which recombinant DNA technology is used to develop rationally designed
protein medications along with the potential benefits and difficulties of
therapy with biologic agents, and (3) to provide a short review of the medications
under development for psoriasis.
Data Sources The pertinent literature was reviewed with particular emphasis on published,
randomized, and placebo-controlled trials. Phase 1 and early phase 2 trials
were also included in our review when more stringent studies were not available.
Studies presented as peer-reviewed abstracts at major conferences were also
reviewed.
Conclusions With the development of recombinant DNA techniques, it has become possible
to develop new biologic therapies that can be designed to specifically alter
physiological responses. These new drugs are in use in many different medical
fields and will soon be available for the treatment of dermatological diseases,
primarily psoriasis. Dermatologists should be familiar with the potential
benefits and risks of these therapies to make rational decisions concerning
their use in the treatment of their patients with psoriasis.
From the Department of Dermatology, Feinberg School of Medicine, Chicago,
Ill.
RELATED ARTICLE
New Developments in the Treatment of Psoriasis
Mark Lebwohl
Arch Dermatol. 2002;138(5):686-688.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Pharmacokinetics and Pharmacodynamics of Multiple Weekly Subcutaneous Efalizumab Doses in Patients With Plaque Psoriasis
Mortensen et al.
J Clin Pharmacol 2005;45:286-298.
ABSTRACT
| FULL TEXT
Psoriasis treatment: current and emerging directed therapies
Winterfield et al.
Ann Rheum Dis 2005;64:ii87-ii90.
ABSTRACT
| FULL TEXT
Treatment of Psoriasis With Alefacept: Correlation of Clinical Improvement With Reductions of Memory T-Cell Counts
Gordon et al.
Arch Dermatol 2003;139:1563-1570.
ABSTRACT
| FULL TEXT
Immunomodulatory drugs for psoriasis
Boehncke
BMJ 2003;327:634-635.
FULL TEXT
New Developments in the Treatment of Psoriasis
Lebwohl
Arch Dermatol 2002;138:686-688.
FULL TEXT
|
